缺血性卒中后抗凝仍复发者:左心耳封堵与标准治疗的比较
这项倾向评分匹配队列研究比较了非瓣膜性房颤患者在接受口服抗凝治疗(OAT)期间仍发生缺血性卒中后,经皮左心耳封堵(LAAO)与继续单独OAT的卒中预防效果。LAAO组433例与对照组433例匹配,2年随访期间LAAO组年化缺血性卒中发生率为2.8%/患者年,对照组为8.9%/患者年,LAAO与缺血性卒中风险降低相关(HR 0.33,95%CI 0.19-0.58,P<.001)。作者认为需要随机临床试验数据来证实LAAO可能是有前景的治疗选择。
要点
- 非瓣膜性房颤患者OAT期间仍发生血栓栓塞事件后,LAAO与继续单独OAT相比缺血性卒中风险更低(HR 0.33)。
- LAAO组年化缺血性卒中发生率为2.8%/患者年,对照组为8.9%/患者年。
- LAAO后67%(290例)患者停用OAT,33%(143例)继续OAT作为辅助治疗。
核心结论
- 在非瓣膜性房颤且既往接受OAT期间仍发生血栓栓塞事件的患者中,LAAO与继续单独OAT相比与缺血性卒中风险降低相关。
- 作者认为需要随机临床试验数据来证实LAAO可能是有前景的治疗选择。
研究设计与样本
- 这项队列研究采用倾向评分匹配,将STR-OAC LAAO队列(国际协作,21个中心,2010至2022年接受LAAO的患者)与既往发表对照队列(国际协作研究者发起的前瞻性研究)进行匹配。
- STR-OAC LAAO队列中随访超过3个月的患者纳入分析。
- 对照队列包括非瓣膜性房颤、近期缺血性卒中或短暂性脑缺血发作、随访超过3个月且在索引事件前服用OAT的患者。
- 分析对性别、年龄、高血压、糖尿病和CHA2DS2-VASc评分的不平衡进行了调整。
- STR-OAC LAAO队列433例患者与对照组1140例中的433例(38%)匹配。
主要发现
- STR-OAC LAAO组患者平均(SD)年龄72(9)岁,女性171例(39%),男性262例(61%),平均(SD)CHA2DS2-VASc评分5.0(1.6)。
- 2年随访期间,50例患者发生缺血性卒中;STR-OAC LAAO组年化事件发生率为2.8%/患者年,对照组为8.9%/患者年。
- LAAO与缺血性卒中风险降低相关(HR 0.33;95%CI 0.19-0.58;P<.001)。
- LAAO后290例(67%)停用OAT,剩余143例(33%)继续OAT作为辅助治疗。
临床怎么用
- 作者认为,对于非瓣膜性房颤且既往接受OAT期间仍发生血栓栓塞事件的患者,LAAO可能是很有前景的治疗选择,但需要随机临床试验数据证实。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Patients with atrial fibrillation (AF) who have ischemic stroke despite taking oral anticoagulation therapy (OAT) have a very high risk of recurrence. Left atrial appendage occlusion (LAAO) is a mechanical stroke prevention strategy that may provide additional protection in patients with thromboembolic events under OAT. OBJECTIVE: To compare percutaneous LAAO with continuing OAT alone regarding stroke prevention in patients with AF who had a thromboembolic event despite taking OAT. DESIGN, SETTING, AND PARTICIPANTS: This cohort study was a propensity score-matched comparison of the STR-OAC LAAO cohort, an international collaboration of 21 sites combining patients from multiple prospective registries of patients who underwent LAAO between 2010 and 2022. STR-OAC LAAO cohort patients who had follow-up longer than 3 months were propensity score-matched to a previously published control cohort comprising patients from an established international collaboration of investigator-initiated prospective studies. This control cohort included patients with nonvalvular AF, recent ischemic stroke or transient ischemic attack, and follow-up longer than 3 months who were taking OAT before the index event. Analyses were adjusted for imbalances in gender, age, hypertension, diabetes, and CHA2 DS2-VASc score. EXPOSURE: Left atrial appendage occlusion vs continuation of oral anticoagulation therapy alone (control group). MAIN OUTCOMES AND MEASURES: The primary outcome was time to first ischemic stroke. RESULTS: Four hundred thirty-three patients from the STR-OAC LAAO cohort (mean [SD] age, 72 [9] years; 171 [39%] females and 262 [61%] males; mean [SD] CHA2 DS2-VASc score, 5.0 [1.6]) were matched to 433 of 1140 patients (38%) from the control group. During 2-year follow-up, 50 patients experienced ischemic stroke: an annualized event rate of 2.8% per patient-year in the STR-OAC LAAO group vs 8.9% per patient-year in the control group. Left atrial appendage occlusion was associated with a lower risk of ischemic stroke (hazard ratio, 0.33; 95% CI, 0.19-0.58; P < .001) compared with the control group. After LAAO, OAT was discontinued in 290 patients (67%), and the remaining 143 patients (33%) continued OAT after LAAO as an adjunctive therapy. CONCLUSIONS AND RELEVANCE: In patients with nonvalvular AF and a prior thromboembolic event despite taking OAT, LAAO was associated with a lower risk of ischemic stroke compared with continued OAT alone. Randomized clinical trial data are needed to confirm that LAAO may be a promising treatment option for this population with a very high risk of stroke.
引用
- Maarse M, Seiffge DJ, Werring DJ, et al. Left Atrial Appendage Occlusion vs Standard of Care After Ischemic Stroke Despite Anticoagulation. JAMA Neurol. 2024. PMID: 39374446. doi:10.1001/jamaneurol.2024.2882
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。